- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01659177
A Study of LY2140023 in Healthy Participants
August 17, 2021 updated by: Denovo Biopharma LLC
The Effect of Food on the Pharmacokinetics of LY2140023 and LY404039 in Healthy Subjects After Administration of the Commercial Tablet Formulation of LY2140023
The study will evaluate the effect of food on absorption of LY2140023 in blood.
This study involves a single dose of 80 mg LY2140023 taken as a tablet by mouth on 2 occasions, once on an empty stomach and once after eating breakfast.
There is a minimum 3 day washout between doses.
This study will last approximately 16 days not including screening.
Screening is required within 30 days prior to the start of the study.
Study Overview
Study Type
Interventional
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Allschwil, Switzerland, CH-4123
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Are healthy males or females, as determined by medical history and physical examination
- Male participants agree to use a reliable method of birth control during the study and for 3 months following the last dose of LY2140023, and agree not to donate sperm for 3 months following the last dose of LY2140023
Female participants:
- of childbearing potential, who test negative for pregnancy at screening and who agree to use a reliable method of birth control during the study and for 3 months following the last dose of LY2140023
- of non-childbearing potential i.e. postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy or confirmed tubal occlusion (not tubal ligation). Postmenopausal is defined as spontaneous amenorrhea for at least 12 months, and a plasma follicle-stimulating hormone (FSH) level >40 milli-international units per milliliter (mIU/mL), unless the participant is taking hormone replacement therapy
- have given written informed consent approved by Lilly and the chosen ethical review board (ERB)
Exclusion Criteria:
- Are currently enrolled in, have completed or discontinued within the last 90 days from, a clinical trial involving an investigational product other than the investigational product used in this study; or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
- Have known allergies to LY2140023 or LY404039, related compounds, activated charcoal, or any components of the formulation
- Are persons who have previously withdrawn from this study or any other study investigating LY2140023 after receiving at least 1 dose of LY2140023
- Show evidence or any history of significant active neuropsychiatric disease (for example, manic depressive illness, schizophrenia, depression)
Have increased risk of seizures based on a history of:
- one or more seizures (except for a single simple febrile seizure [lacking focality and lasting less than 15 minutes, not associated with a central nervous system (CNS) infection or severe metabolic disturbance] as a child between ages 6 months to 5 years)
- head trauma with loss of consciousness or a post-concussive syndrome within 1 year or lifetime history of head trauma with persistent neurological deficit (focal or diffuse)
- CNS infection, uncontrolled migraine or transient ischemic attack (TIA) within 1 year; stroke with persistent neurological deficit (focal or diffuse), uncontrolled migraine is defined as migraine attacks that produce headache lasting up to 72 hours and are often accompanied by associated symptoms (nausea, photophobia, and phonophobia) that impair well-being and disrupt social functioning. TIA is defined as "mini-stroke" caused by temporary disturbance of blood supply to an area of the brain, which results in a sudden, brief decrease in brain function
- CNS infection with persistent neurological deficit (focal or diffuse)
- brain surgery
- electroencephalogram (EEG) with paroxysmal (epileptiform) activity (isolated spikes waves, repetitive bursts of sharp waves, paroxysmal activity, frank seizures, spike-wave complexes, or sharp-slow wave complexes, or as locally defined)
- brain structural lesion, including developmental abnormalities, as determined by examination or imaging studies (except hydrocephalus treated by shunt and without neurological deficit)
- Show evidence of active renal disease (for example, diabetic renal disease, polycystic kidney disease) or creatinine clearance less than 90 milliliters per minute (mL/min) as determined by the Cockroft Gault formula
- Show evidence or any history of known substance dependence or abuse at any time (according to Diagnostic and Statistical Manual of Mental Disorders [DSM-IV] diagnosis), or regularly use known drugs of abuse and/or show positive findings on urinary drug screening
- Have a clinically significant abnormality in the neurological examination
- Participants judged prior to randomization to be at suicidal risk by the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LY2140023 fasting
Single oral dose of 80 mg LY2140023 given in fasted state
|
Administered orally
|
Experimental: LY2140023 + food
Single oral dose of 80 mg LY2140023 given after standardized high-fat breakfast
|
Administered orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics: Maximum concentration (Cmax) of LY2140023 and LY404039
Time Frame: Up to 24 hours after administration of study drug
|
Up to 24 hours after administration of study drug
|
Pharmacokinetics: Area under the concentration curve (AUC) of LY2140023 and LY404039
Time Frame: Up to 24 hours after administration of study drug
|
Up to 24 hours after administration of study drug
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2012
Primary Completion (Anticipated)
September 1, 2012
Study Completion (Anticipated)
September 1, 2012
Study Registration Dates
First Submitted
August 3, 2012
First Submitted That Met QC Criteria
August 3, 2012
First Posted (Estimate)
August 7, 2012
Study Record Updates
Last Update Posted (Actual)
August 23, 2021
Last Update Submitted That Met QC Criteria
August 17, 2021
Last Verified
September 1, 2012
More Information
Terms related to this study
Other Study ID Numbers
- 14511
- H8Y-MC-HBDJ (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Participants
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
Insmed IncorporatedRecruitingHealthy ParticipantsUnited States
-
Aeovian Pharmaceuticals, Inc.RecruitingHealthy ParticipantsAustralia
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruitingHealthy ParticipantsChina
-
CelgeneNot yet recruitingHealthy ParticipantsUnited States
-
Bristol-Myers SquibbNot yet recruiting
-
AstraZenecaParexelRecruiting
-
ProMis Neurosciences, IncRecruiting
-
Novo Nordisk A/SRecruitingHealthy ParticipantsCanada
-
Novo Nordisk A/SRecruiting
Clinical Trials on LY2140023
-
Denovo Biopharma LLCCompleted
-
Denovo Biopharma LLCCompleted
-
Denovo Biopharma LLCCompleted
-
Denovo Biopharma LLCTerminated
-
Eli Lilly and CompanyTerminatedSchizophreniaGermany, Spain, United States, Sweden, Austria, France, Poland, Puerto Rico, Romania, Brazil, Greece
-
Denovo Biopharma LLCTerminatedSchizophreniaUnited States, Mexico, Russian Federation, Puerto Rico, Ukraine
-
Denovo Biopharma LLCCompleted
-
Eli Lilly and CompanyCompletedHealthy SubjectsUnited Kingdom
-
NYU Langone HealthTerminatedPost-traumatic Stress Disorder
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)Completed